We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -0.48% | 206.50 | 207.50 | 210.00 | 209.50 | 204.50 | 207.50 | 410,362 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | 23.75M | -50.35M | -0.1839 | -11.28 | 568.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/10/2018 18:26 | 75000 buy this afternoon | lendmeafiver | |
04/10/2018 07:39 | Positive RNS today. | zeusfurla | |
27/9/2018 10:27 | Without news I expect this will drift down a bit. | countless | |
15/9/2018 23:12 | Plus resTORbio heading up on the Nasdaq also. | lendmeafiver | |
15/9/2018 20:20 | From citywire: PureTech Health (PRTC) shares are ‘too cheap’ following strong progress since the start of the year, including a potential $1 billion licensing deal with Roche, says Liberum. Analyst Roger Franklin retained his ‘buy’ recommendation and target price of 248p on the shares, which were trading at 158.8p yesterday. He said PureTech was ‘pioneering a new way to pursue biotech and pharma research and development’ and ‘given the nature of the company, the financial results are as usual a sideshow to the main focus which is the progress of its affiliates and internal pipeline’. Franklin noted the company’s more than $1 billion potential licensing deal with Roche which ‘demonstrates strong progress since the start of the year’. ‘The shares remain too cheap in our view, with our asset based target price of 248p offering more than 50% upside,’ he said. | rambutan2 | |
14/9/2018 15:16 | The buying continues today, looking good | lendmeafiver | |
13/9/2018 20:25 | Bit of buying since the Half Year Results, not surprising. | lendmeafiver | |
11/9/2018 22:37 | Jefferies Buy 255.00 Reiteration | lendmeafiver | |
11/9/2018 09:40 | Cash in in bank wrong exression but their possition is improving in leaps and bounds - total assets up 28% total liabilites down 21% and after a very busy period costs/loss down 2.7% Seems stran to me me that healthcare based businesses are flying with no knock on effect here given strong pipeline that reaches out to some mass markets. | countless | |
11/9/2018 09:12 | “Moon shots” is an excellent description! | lendmeafiver | |
11/9/2018 09:07 | agreed - patience is required but we have several moon shots all jockying for position at the launch pad. | edwardt | |
11/9/2018 08:56 | Even Follica gets a “significant progress towards the initiation of a pivotal study in androgenetic alopecia” normally they downplay that opportunity, plus have included it in the next 12 month milestone section. Newsflow over the next 12 months over all divisions now very significant. | lendmeafiver | |
11/9/2018 08:44 | puretech net cash is half that right? other cash is in subsidiaries but i take your point they have been very busy and good to see the cash burn has not accelerated with increased activity. lets hope this one has a shortened j curve compared to most private equity investments... | edwardt | |
11/9/2018 07:44 | Excellent overview - $417m in the bank and an excellent pipleine all at a market cap of £444m what is there not to like. | countless | |
10/9/2018 15:46 | Yes, optimistic | lendmeafiver | |
10/9/2018 15:12 | everyone looking forward to tomorrow!! | edwardt | |
04/9/2018 20:19 | Thanks for that link, will certainly take a look. | lendmeafiver | |
04/9/2018 20:12 | For anyone interested, it's 15.15 UK time: resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Wells Fargo 2018 Healthcare Conference on Wednesday, September 5, 2018 at 10:15 a.m. ET in Boston, MA. A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at . An archived replay will be available for at least 30 days following the presentation. | rambutan2 | |
29/8/2018 09:34 | Ok, two weeks | lendmeafiver | |
28/8/2018 21:07 | Should be later this week, look forward to it. | lendmeafiver | |
28/8/2018 15:18 | According to MarketScreener - interim results were due out today. hxxps://www.marketsc Don't see any sign of them so far? | ascoyne | |
28/8/2018 14:47 | Last year the interims were released on the 30th, although no advance notice so far. I would expect them to be pretty upbeat about progress on a number of fronts. | rambutan2 | |
28/8/2018 13:43 | What is the next expected area of newsflow here? gelesis? | lendmeafiver | |
19/8/2018 16:50 | Tipped over the weekend | countless |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions